These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 35817017)
1. Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Lee YH Pharmacology; 2022; 107(11-12):537-544. PubMed ID: 35817017 [TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials. Lee YH; Song GG Z Rheumatol; 2022 Feb; 81(1):71-76. PubMed ID: 33340056 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis. Song GG; Lee YH Int J Clin Pharmacol Ther; 2021 Sep; 59(9):610-617. PubMed ID: 33993905 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis. Lee YH; Song GG Z Rheumatol; 2021 Oct; 80(8):776-784. PubMed ID: 32648054 [TBL] [Abstract][Full Text] [Related]
5. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis. Lee YH; Song GG Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216 [TBL] [Abstract][Full Text] [Related]
6. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis. Lee YH; Song GG Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. Sung YK; Lee YH J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Lee YH; Song GG Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis. Sung YK; Lee YH Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188 [TBL] [Abstract][Full Text] [Related]
11. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis. Lee YH; Song GG Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. Ho Lee Y; Gyu Song G J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Song GG; Choi SJ; Lee YH Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506 [TBL] [Abstract][Full Text] [Related]
14. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Lee YH; Song GG Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis. Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267 [TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492 [TBL] [Abstract][Full Text] [Related]
18. Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Ungprasert P; Erwin PJ; Koster MJ Clin Rheumatol; 2017 Jul; 36(7):1569-1577. PubMed ID: 28551823 [TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the treatment of active ankylosing spondylitis in adults. Mohanakrishnan R; Beier S; Deodhar A Expert Rev Clin Immunol; 2022 Mar; 18(3):273-280. PubMed ID: 35152808 [TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]